Suchergebnisse - "Janjigian, Yelena Y"

PubPharm (209)

1

Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2024

von Vitiello, G. | Jayaprakasam, V. | Tang, L. | +11

2

18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Cytryn, S. | Pandit-Taskar, N. | Lumish, M. | +16

3

Patient metabolic profile defined by liver and muscle 18F-FDG PET avidity is independently associated with overall survival in gastric cancer

enthalten in: Gastric cancer | 2024

von Vitiello, G. | Jayaprakasam, V. | Tang, L. | +11

4

Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma

enthalten in: The Annals of thoracic surgery | 2024

von Fick, C. | Dunne, E. | Sihag, S. | +8

5

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma : 3-Year Follow-Up of the Phase III CheckMate 649 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Janjigian, Y. | Ajani, J. | Moehler, M. | +23

6

Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer

enthalten in: Journal of the National Cancer Institute | 2024

von Lumish, M. | Walch, H. | Maron, S. | +22

7

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585) : an interim analysis of the multicentre, double-blind, randomised phase 3 study

enthalten in: The Lancet. Oncology | 2024

von Shitara, K. | Rha, S. | Wyrwicz, L. | +22

8

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Moehler, M. | Xiao, H. | Blum, S. | +21

9

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma : interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

enthalten in: Lancet (London, England) | 2023

von Janjigian, Y. | Kawazoe, A. | Bai, Y. | +18

CommentIn: Lancet. 2023 Dec 9;402(10418):2168-2170. - PMID 37871605

10

Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer : a case series

enthalten in: International journal of surgery (London, England) | 2023

von Boerner, T. | Carr, R. | Hsu, M. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[21]